Cargando…

Physician characteristics associated with treatment initiation patterns in idiopathic pulmonary fibrosis

Pirfenidone and nintedanib are oral antifibrotic agents approved for the treatment of idiopathic pulmonary fibrosis (IPF). Real-world data on factors that influence IPF treatment decisions are limited. Physician characteristics associated with antifibrotic therapy initiation following an IPF diagnos...

Descripción completa

Detalles Bibliográficos
Autores principales:	LaCamera, Peter P, Limb, Susan L, Haselkorn, Tmirah, Morgenthien, Elizabeth A, Stauffer, John L, Wencel, Mark L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2019
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6764076/ https://www.ncbi.nlm.nih.gov/pubmed/31558049 http://dx.doi.org/10.1177/1479973119879678

Ejemplares similares

Real-World Practice Patterns for Prevention and Management of Potential Adverse Events with Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
por: Wencel, Mark L., et al.
Publicado: (2018)

Changes in Neutrophil–Lymphocyte or Platelet–Lymphocyte Ratios and Their Associations with Clinical Outcomes in Idiopathic Pulmonary Fibrosis
por: Nathan, Steven D., et al.
Publicado: (2021)

FVC variability in patients with idiopathic pulmonary fibrosis and role of 6-min walk test to predict further change
por: Nathan, Steven D., et al.
Publicado: (2020)

A Phase 1b Study of Vismodegib with Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
por: Prasse, Antje, et al.
Publicado: (2019)

Patient and site characteristics associated with pirfenidone and nintedanib use in the United States; an analysis of idiopathic pulmonary fibrosis patients enrolled in the Pulmonary Fibrosis Foundation Patient Registry
por: Holtze, Colin H., et al.
Publicado: (2020)

Cardiovascular Risks, Bleeding Risks, and Clinical Events from 3 Phase III Trials of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
por: Glassberg, Marilyn K., et al.
Publicado: (2019)

Correction to: Cardiovascular Risks, Bleeding Risks, and Clinical Events from 3 Phase III Trials of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
por: Glassberg, Marilyn K., et al.
Publicado: (2019)

Anti-fibrotic therapy and lung transplant outcomes in patients with idiopathic pulmonary fibrosis
por: Astor, Todd L., et al.
Publicado: (2023)

Clinical Manifestations of Subjects With the Non-Specific Pulmonary Function Test Pattern
por: Tasch, James, et al.
Publicado: (2023)

Pulmonary edema during the Boston Marathon
por: Aoun, Joe, et al.
Publicado: (2019)

Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis
por: Lancaster, Lisa H., et al.
Publicado: (2017)

Idiopathic Pulmonary Fibrosis for Cardiologists: Differential Diagnosis, Cardiovascular Comorbidities, and Patient Management
por: van Cleemput, Johan, et al.
Publicado: (2018)

Global Methylation Patterns in Idiopathic Pulmonary Fibrosis
por: Rabinovich, Einat I., et al.
Publicado: (2012)

Safety of nintedanib added to pirfenidone treatment for idiopathic pulmonary fibrosis
por: Flaherty, Kevin R., et al.
Publicado: (2018)

Cough in Idiopathic Pulmonary Fibrosis
por: Mann, Jennifer, et al.
Publicado: (2021)

Potential Delays in Diagnosis of Idiopathic Pulmonary Fibrosis in Medicare Beneficiaries
por: Mooney, Joshua, et al.
Publicado: (2019)

Cellular Senescence in Idiopathic Pulmonary Fibrosis
por: Kellogg, D. L., et al.
Publicado: (2021)

Incidence of anaphylaxis and accidental peanut exposure: A systematic review
por: Muraro, Antonella, et al.
Publicado: (2021)

An educational initiative to improve the team-based care of patients with idiopathic pulmonary fibrosis
por: Fernández Pérez, Evans R., et al.
Publicado: (2018)

A Predictive Model for Acute Respiratory Distress Syndrome Mortality Using Red Cell Distribution Width
por: Alkhatib, Ala, et al.
Publicado: (2020)

Incidence and Clinical Characteristics of Pulmonary Hypertension in Patients with Idiopathic Pulmonary Fibrosis
por: Yan, Wei, et al.
Publicado: (2015)

Idiopathic pulmonary fibrosis: Physicians' perceptions of patient treatment with recently approved drugs
por: Audibert, Céline, et al.
Publicado: (2016)

Pirfenidone treatment of idiopathic pulmonary fibrosis
por: Gan, Ye, et al.
Publicado: (2011)

Idiopathic Pulmonary Fibrosis (IPF): An Overview
por: Barratt, Shaney L., et al.
Publicado: (2018)

Idiopathic pulmonary fibrosis
por: Meltzer, Eric B, et al.
Publicado: (2008)

Idiopathic Pulmonary Fibrosis
por: Lynch, Joseph P., et al.
Publicado: (2011)

Impact of Delayed Admission to the Intensive Care Unit from the Emergency Department upon Sepsis Outcomes and Sepsis Protocol Compliance
por: Agustin, Michael, et al.
Publicado: (2017)

Use of nintedanib in patients with idiopathic pulmonary fibrosis: Initial Indian experience
por: Mullerpattan, Jai B, et al.
Publicado: (2019)

Development and Initial Validation Analyses of the Living with Idiopathic Pulmonary Fibrosis Questionnaire
por: Swigris, Jeffrey J., et al.
Publicado: (2020)

An Open-Label, Phase II Study of the Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (PIPF-002)
por: Gotfried, Mark H., et al.
Publicado: (2018)

Clinical characteristics, comorbidities, and outcomes in patients with idiopathic pulmonary fibrosis
por: Alhamad, Esam H., et al.
Publicado: (2020)

Association between dexmedetomidine use for the treatment of alcohol withdrawal syndrome and intensive care unit length of stay
por: Yavarovich, Ekaterina R., et al.
Publicado: (2019)

Hospitalizations in patients with idiopathic pulmonary fibrosis
por: Kim, Hyun J., et al.
Publicado: (2021)

Effectiveness of Pharmacist–Physician Collaborative Management for Patients With Idiopathic Pulmonary Fibrosis Receiving Pirfenidone
por: Satsuma, Yukari, et al.
Publicado: (2020)

ATP12A: Connecting Mucus and Fibrosis in Idiopathic Pulmonary Fibrosis
por: Zabner, Joseph, et al.
Publicado: (2023)

The epithelium in idiopathic pulmonary fibrosis: breaking the barrier
por: Camelo, Ana, et al.
Publicado: (2014)

Pirfenidone Treatment in Individuals with Idiopathic Pulmonary Fibrosis: Impact of Timing of Treatment Initiation
por: Maher, Toby M., et al.
Publicado: (2019)

Erratum: Use of nintedanib in patients with idiopathic pulmonary fibrosis: Initial Indian experience
Publicado: (2021)

Microscopic polyangiitis initially presenting with idiopathic pulmonary fibrosis: a case report
por: Shao, Chi, et al.
Publicado: (2023)

Objective cough frequency in Idiopathic Pulmonary Fibrosis
por: Key, Angela L, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_11o0gn34qi2gjhudk11tvl0ur1